Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Saved in:
| Title: | Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. |
|---|---|
| Authors: | Wainberg ZA; Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles Medical Center, David Geffen School of Medicine, 2825 Santa Monica Blvd., Suite 200, Santa Monica, Los Angeles, CA, 90404-2429, USA. ZWainberg@mednet.ucla.edu., Kang YK; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Qin S; Nanjing Tianyinshan Hospital, The 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, China., Yamaguchi K; Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Kim IH; Department of Oncology, The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea., Saeed A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Oh SC; Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea., Li J; Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China., Turk HM; Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey., Teixeira A; Gastroenterology Division, Hospital da Senhora da Oliveira, Guimarães, Portugal., Hitre E; Department of Medical Oncology and Clinical Pharmacology 'B', National Institute of Oncology, Budapest, Hungary., Udrea AA; Medical Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania., Cardellino GG; Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy., Sanchez RG; Department of Medical Oncology, Catalan Institute of Oncology, Girona, Spain., Zahlten-Kümeli A; Amgen Inc, Thousand Oaks, CA, USA., Taylor K; Amgen Inc, Uxbridge, UK., Enzinger PC; Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. |
| Source: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2024 May; Vol. 27 (3), pp. 558-570. Date of Electronic Publication: 2024 Feb 03. |
| Publication Type: | Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article |
| Journal Info: | Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1436-3305 |
|---|---|
| DOI: | 10.1007/s10120-024-01466-w |
